MINIjectTM is designed to significantly reduce IOP by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is swift and predictable using a trigger in a single-step procedure.
MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability.
The MINIject first-in-man clinical trial has completed enrolment. Primary endpoint results are expected in mid-2018. Please contact us for further information.